Our latest insights

Australia’s R&D policy is back in focus ahead of the Federal Budget, with the SERD review highlighting declining investment and the need for reform. While no immediate changes to the R&D Tax Incentive have been announced, businesses should watch for potential policy shifts and ensure strong governance, compliance, and documentation under the current framework.

Compare key R&D tax incentive regimes worldwide. See how global innovation funding, benefit levels, and eligibility differ across major jurisdictions.

R&D Tax Transparency insights driving innovation in Australia’s agribusiness and food sector.

With the 30 April 2026 registration deadline approaching, companies that performed R&D activities in the year ended 30 June 2025 should be reviewing eligibility, documentation and governance now to preserve their entitlement under the RDTI.

The Australian Government has released exposure draft legislation proposing to exclude certain tobacco, vaping and gambling-related activities from the Research and Development Tax Incentive (RDTI). The intent is to ensure public funding does not support innovation that promotes harmful consumption behaviours, while maintaining eligibility for genuine harm-minimisation initiatives.

Built on world-class research and clinical trials, Australia’s biotech industry is increasingly shifting towards commercialisation, global expansion, and long-term growth.

The 2025 financial year marked a dynamic chapter for Australia’s Research & Development Tax Incentive (RDTI), with notable shifts in policy, compliance, and industry engagement. As innovation continues to drive economic growth, staying informed on the evolving R&D landscape has never been more critical for Australian businesses.

In this episode, Corporate Tax Partner Vince Tropiano, Global Trade Partner Richard Nutt and Innovation Incentives Director Simone Barker discuss the Australian economy and how tariffs are impacting Australian manufacturing businesses – and what they can do to mitigate risks.

Last chance to register your 30 June 2024 R&D activities

The biotech industry faces significant challenges, including regulatory pressures, supply chain disruptions, rising costs and shifting investment landscapes.

The Australian Parliament recently passed legislation to introduce two significant tax incentives aimed at bolstering Australia’s critical minerals and hydrogen production sectors. The incentives form a significant part of the Government’s ’Future Made in Australia‘ policy.

On 12 February 2025, the Australian Government released its Strategic Examination of Research & Development (R&D) discussion paper. Public consultations on the discussion paper are officially open, with written submissions due by 11 April 2025.